An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Trial Profile

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chimerix
  • Most Recent Events

    • 01 Feb 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 30 Jan 2015 According to Chimerix media release, company announced after discussing with US FDA, to cease further participation of all current and future trials of brincidofovir for ebola virus disease.
    • 16 Dec 2014 Status changed from not yet recruiting to recruiting according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top